公开(公告)号：US20220160721A1

公开(公告)日：2022-05-26

申请号：US17515979

申请日：2021-11-01

Applicant: Epizyme, Inc.

Inventor： Jesse SMITH ,  Heike KEILHACK ,  Scott RIBICH

IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4412 ,  A61K9/00 ,  A61K31/551 ,  A61K31/553 ,  A61K31/496 ,  G01N33/574 ,  A61K31/4545 ,  A61K31/5386 ,  A61K31/4439 ,  A61K31/4433 ,  A61K45/06

Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190038633A1

公开(公告)日：2019-02-07

申请号：US16075855

申请日：2017-02-08

Applicant: Epizyme, Inc.

Inventor： Jesse SMITH ,  Heike KEILHACK ,  Scott RIBICH

IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4412 ,  A61K31/496 ,  A61K31/551 ,  A61K31/553 ,  A61K9/00

Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20200323865A1

公开(公告)日：2020-10-15

申请号：US16789815

申请日：2020-02-13

Applicant: Epizyme, Inc.

Inventor： Jesse SMITH ,  Heike KEILHACK ,  Scott RIBICH

IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4412 ,  A61K9/00 ,  A61K31/551 ,  A61K31/553 ,  A61K31/496 ,  G01N33/574 ,  A61K31/4545 ,  A61K31/5386 ,  A61K31/4439 ,  A61K31/4433 ,  A61K45/06

Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190270797A1

公开(公告)日：2019-09-05

申请号：US16320447

申请日：2017-07-25

Applicant: EPIZYME, INC.

Inventor： Alexandra GRASSIAN ,  Scott RIBICH ,  Jesse SMITH ,  Darren Martin HARVEY

IPC: C07K16/22 ,  G01N33/50 ,  A61P35/00 ,  A61K31/7105 ,  A61K31/711

Abstract: The present disclosure provides novel cancer therapies. The treatment of cancers harboring EP300 mutations with CREBBP inhibition therapy is described.